Clik here to view.
HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a...
HANGZHOU, China HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced results of its Phase 1a study of HF1K16 showing three...
View ArticleClik here to view.
ImmuneOncia Announces Phase 1 Results of CD47 Antibody at ESMO 2023
SEOUL, South Korea ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at the European...
View ArticleClik here to view.
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival...
TOKYO & BASKING RIDGE, N.J. Positive results from the pivotal TROPION-Breast01 phase 3 trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically...
View ArticleClik here to view.
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy...
TOKYO & BASKING RIDGE, N.J. Positive results from the pivotal TROPION-Lung01 phase 3 trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for...
View ArticleClik here to view.
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2...
TOKYO & BASKING RIDGE, N.J. Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan) continued to demonstrate clinically meaningful and...
View ArticleClik here to view.
Avistone Announces Phase II Results for Vebreltinib, a c-Met Tyrosine Kinase...
BEIJING Avistone Biotechnology Co., Ltd. (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, announced preliminary results of the Phase...
View ArticleClik here to view.
Iksuda Therapeutics宣布在IKS014的1期试验中对表达HER2的晚期实体瘤患者进行了首例患者给药
英格兰纽卡斯尔 (美国商业资讯)– 具有增强肿瘤特异性的一流抗体药物偶联物（ADC）开发商Iksuda Therapeutics（Iksuda）今天宣布，第一位患者已经完成了IKS014的第一个治疗周期。IKS014是一种适用于晚期HER2+实体瘤患者的人体表皮生长因子受体2（HER2）ADC。此前，Fosun...
View ArticleClik here to view.
日本の神谷町脳神経外科クリニック、ZAP-X®ジャイロスコープラジオサージェリー®プラットフォームで脳腫瘍患者様の治療を開始
カリフォルニア州サンカルロス （ビジネスワイヤ） —...
View ArticleClik here to view.
Kamiyacho Neurosurgical Clinic in Japan Celebrates First Brain Tumor Patient...
SAN CARLOS, Calif. ZAP Surgical, a leading innovator in the field of surgical robotics, today announced the first patient treatment using the groundbreaking ZAP-X® Gyroscopic Radiosurgery® platform...
View ArticleClik here to view.
Elpiscience Announces Three Poster Presentations at Society for Immunotherapy...
SHANGHAI & SUZHOU, China & GERMANTOWN, Md. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation...
View ArticleClik here to view.
Biocytogen Announces 16 Poster Presentations and Booth Exhibition at SITC 2023
BEIJING & WALTHAM, Mass. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that the company will be presenting 16 posters and exhibiting at booth 223 at...
View ArticleClik here to view.
イクスーダ・セラピューティクス、HER2発現の進行性固形がん患者を対象としたIKS014の第1相試験で最初の患者への投与を発表
英国ニューカッスル （ビジネスワイヤ） —...
View ArticleClik here to view.
Lubrizol’s Apisolex™ Polymer Wins Finished Formulation Award at CPhI Barcelona
CLEVELAND Lubrizol Life Science Health, a leading pharmaceutical company, has won the Finished Formulation Award at CPhI Barcelona for its innovative technology – Apisolex™ Polymer solubilizing...
View ArticleClik here to view.
AGCバイオロジクス、メディジーンの新しい細胞治療製品をサポートするTCR-T細胞サービス契約を締結
米シアトル （ビジネスワイヤ） — バイオ医薬品開発・受託製造企業（CDMO）大手のAGCバイオロジクスは、メディジーン（、FSE略称 MDG1、プライム・スタンダード）と新たなサービス契約を締結することを発表しました。同契約のもと、AGCバイオロジクスは、固形がん治療に特化した次世代治療向け製品のための自己製剤を提供し、メディジーンのIND申請と臨床試験をサポートします。...
View ArticleClik here to view.
武田薬品工業: 2023年度上期業績を公表 － 通期業績予想を修正、マネジメントガイダンスの達成に向けて順調に推移
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TOKYO：4502/NYSE：TAK）は、本日、2023年度上期（2023年4月1日～2023年9月30日）の業績を公表しましたのでお知らせします。当社は、財務ベースおよびCoreの通期業績予想を修正し、CERベースでのCore増減率を指標とする通期マネジメントガイダンスを維持します。...
View ArticleClik here to view.
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2023 (six months ended September 30, 2023), updating reported and...
View ArticleClik here to view.
Takeda公布2023财年上半年业绩；更新全年预测，继续稳步实现管理层指引
日本大阪和马萨诸塞州坎布里奇 (美国商业资讯)– Takeda (TOKYO:4502/NYSE:TAK)今天公布了2023财年上半年（截至2023年9月30日的六个月）的财务业绩，更新了之前报告的预测和核心预测，并再次确认了按CER计算的核心利润变化的管理层指引。 Takeda首席执行官Christophe Weber评论道：...
View ArticleClik here to view.
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been...
View ArticleClik here to view.
Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through...
DARMSTADT, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The...
View ArticleClik here to view.
AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku...
NEW YORK AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced it has entered into an...
View Article